市场调查报告书
商品编码
1500527
穿戴式註射器市场:按类型、技术、应用、最终用途、分销管道划分 - 2024-2030 年全球预测Wearable Injector Market by Type (Body Worn Patch Injector, Off Body Worn Patch Injector), Technology (Expanding Battery, Motor Driven, Rotary Pump), Application, End-Use, Distribution Channel - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年穿戴式註射器市场规模为78.4亿美元,预计2024年将达到87.1亿美元,2030年将达到165.6亿美元,复合年增长率为11.26%。
穿戴式註射器是一种创新的医疗设备,旨在以比传统注射器注射更方便、更安全、更少痛苦的方式向患者皮下注射大剂量药物。这些设备紧密贴合患者的身体,具有移动性和灵活性,同时在预设时间内输送大量黏性药物。穿戴式针筒已成为治疗糖尿病、癌症、心血管疾病和自体免疫疾病等慢性疾病的突破性药物传递方法。穿戴式註射器的采用主要是由于需要持续用药的慢性疾病(例如糖尿病和自体免疫疾病)盛行率的上升所推动的。穿戴式註射器的便利性和效率,加上病人对自我给药的偏好,正在支持穿戴式註射器市场的扩张。然而,穿戴式註射器市场面临一些挑战,包括高昂的开发和製造成本以及需要各个地区的监管合规和核准,这些都减缓了新设备进入市场的速度。然而,对生技药品的需求不断增长,通常需要穿戴式註射器提供的精确剂量和持续释放机制,正在开闢新的成长途径。远端医疗和远端患者监护的趋势正在创造对具有连接功能的先进可穿戴注射器的需求。
主要市场统计 | |
---|---|
基准年[2023] | 78.4亿美元 |
预测年份 [2024] | 87.1亿美元 |
预测年份 [2030] | 165.6亿美元 |
复合年增长率(%) | 11.26% |
区域洞察
美洲穿戴式註射器市场的特点是先进的医疗基础设施和高医疗支出。糖尿病和心血管疾病等慢性病的盛行率不断上升,以及对生技药品的高需求正在推动穿戴式註射器在该地区的采用。对医疗设备的监管支援也在穿戴式註射器的快速核准和商业化中发挥关键作用。欧洲拥有强大的医疗保健系统、不断上升的医疗成本以及对先进治疗设备的高度认识,因此穿戴式註射器的采用率正在增加。同时,在医疗基础设施改善、政府措施力度加大以及慢性病发病率上升的推动下,中东和非洲地区的市场正在逐渐扩大。由于医疗保健基础设施的快速改善、可支配收入的增加以及对先进治疗方法的认识不断增强,预计亚太地区将成为穿戴式註射器市场成长最快的地区。在技术进步和政府支持政策的推动下,中国、日本和韩国处于穿戴式註射器采用的前沿。该地区庞大的人口基数,加上慢性病盛行率的不断上升,为市场扩张提供了巨大的机会。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在穿戴式註射器市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检查了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对穿戴式註射器市场供应商的当前状态进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对穿戴式註射器市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[198 Pages Report] The Wearable Injector Market size was estimated at USD 7.84 billion in 2023 and expected to reach USD 8.71 billion in 2024, at a CAGR 11.26% to reach USD 16.56 billion by 2030.
Wearable injectors are innovative medical devices designed to deliver large volumes of drugs subcutaneously to patients in a convenient, safe, and less painful way compared to traditional syringe-based injections. These devices adhere to the patient's body, allowing for mobility and flexibility while administering viscous, high-volume drugs over a predefined time period. Wearable injectors have emerged as a breakthrough in the administration of drugs for chronic diseases such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders. The adoption of wearable injectors is primarily propelled by the rising prevalence of chronic diseases that require continuous medication, such as diabetes and autoimmune diseases. The convenience and efficiency of wearable injectors, coupled with patient preference for self-administration, support the wearable injectors market expansion. Despite the progressive momentum, the wearable injectors market faces several challenges owing to the high cost associated with the development and manufacturing of these devices and the requirement for regulatory compliance and approval across different regions, which can prolong market entry for new devices. However, increasing demand for biologics, which often require precise dosing and slow release mechanisms provided by wearable injectors, opens new avenues for growth. The trend towards telehealth and remote patient monitoring creates demand for advanced wearable injectors with connectivity features.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 7.84 billion |
Estimated Year [2024] | USD 8.71 billion |
Forecast Year [2030] | USD 16.56 billion |
CAGR (%) | 11.26% |
Regional Insights
The wearable injectors market in the Americas is characterized by advanced healthcare infrastructure and high healthcare expenditure. The increasing prevalence of chronic diseases such as diabetes and cardiovascular diseases, coupled with a high demand for biologics, drives the adoption of wearable injectors in the region. Regulatory support for medical devices also plays a vital role in the rapid approval and commercialization of wearable injectors. Europe, with its robust healthcare systems, increased healthcare spending, and high awareness regarding advanced therapeutic devices, demonstrates higher adoption of wearable injectors. The market in the Middle East and Africa, however, is gradually growing, fueled by improving healthcare infrastructure, increasing government initiatives, and rising chronic disease prevalence. The APAC region is anticipated to witness the fastest growth in the wearable injectors market owing to its rapidly improving healthcare infrastructure, increasing disposable income, and growing awareness of advanced treatment methods. China, Japan, and South Korea are at the forefront of the adoption of wearable injectors, driven by technological advancements and supportive government policies. The region's vast population base, coupled with an increasing prevalence of chronic conditions, presents a significant opportunity for market expansion.
Market Insights
The market dynamics represent an ever-changing landscape of the Wearable Injector Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Wearable Injector Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Wearable Injector Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Enable Injections' Wearable Injector
Enable Injections has announced the FDA approval of its Empaveli Injector, a wearable device revolutionizing the administration of subcutaneous therapy. Designed specifically for adults with paroxysmal nocturnal hemoglobinuria, the Empaveli Injector simplifies the treatment process by enabling hands-free delivery of up to 25 mL of medication, suitable for both home and clinical settings. With this advancement, Enable Injections aims to enhance patient care and also extend its reach through additional enFuse partnerships, ultimately elevating patient support on a global scale. [Published On: 2023-10-02]
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
Viridian Therapeutics, Inc., a biotechnology entity dedicated to crafting leading-edge treatments for grave and rare conditions, has collaborated with Enable Injections. This union aims to employ Enable's enFuse wearable drug delivery system, capable of administering up to 25mL, to improve patient care. This collaboration focuses on enhancing drug delivery convenience outside the scope of Viridian's Thyroid Eye Disease (TED) ventures, showing a deep commitment to patient-centered innovation. [Published On: 2023-05-08]
LTS Acquires Sorrel Wearable Injection Device Business
LTS Lohmann, a pharmaceutical technology company, has acquired the Sorrel wearable injector business from Eitan Medical Ltd., based in Netanya, Israel. This acquisition marks a significant leap for LTS, expanding its range of drug delivery solutions to include Sorrel's advanced large-volume wearable injector technologies, which are pivotal for the administration of large molecules and biologics. [Published On: 2023-04-21]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Wearable Injector Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Wearable Injector Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Becton, Dickinson and Company, CCBio, CeQur Corporation, DCA Design International Ltd, Debiotech SA, E3D Elcam Drug Delivery Devices, Enable Injections, Inc., EOFlow Co., Ltd., Gerresheimer AG, Insulet Corporation, LTS Lohmann Therapie-Systeme AG, Medtrum Technologies Inc., Neuma LLC by Kymanox Corporation, Noble International LLC by AptarGroup, Inc., NOVO Engineering, Shaily Engineering Plastics Ltd., SONCEBOZ SA, Stevanato Group S.p.A., Subcuject ApS, Viant, West Pharmaceutical Services, Inc., Ypsomed Holding AG, and ZwickRoell GmbH & Co. KG.
Market Segmentation & Coverage